Why the study?
Anthracyclines are effective chemotherapy agents, but very few cases of idarubicin-induced cardiomyopathy exist.
Highlights a rare case of acute heart failure occurring after the first dose of idarubicin induction chemotherapy.
Idarubicin may trigger acute heart failure after one dose in AML; this case leaves open incidence, predictors, and monitoring needs.
Anthracyclines are an effective chemotherapy agent. However, very few cases of idarubicin-induced cardiomyopathy exist. Herein, we describe a case of first-dose idarubicin-related acute heart failure in a woman with a history of myelodysplastic syndrome converted to acute myeloid leukaemia.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: